101 results match your criteria: "ResMed Science Center[Affiliation]"
Sleep Med X
December 2024
ResMed Science Center, Sydney, Australia.
Chronic Obstr Pulm Dis
September 2024
ResMed Science Center, San Diego, California, United States.
Introduction: Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that adds a significant economic burden to the health care system in the United States. Digital platforms integrated into clinical workflows have demonstrated success in improving patient outcomes in COPD, but few studies have explored the impact of an integrated digital and clinical approach on drivers of direct health care costs (COPD-related prescriptions, emergency department [ED] visits, and hospitalizations) in a real-world setting.
Methods: We conducted a 6-month retrospective matched control analysis to assess the impact of a digital quality improvement (QI) program delivered by clinical pharmacists on health care resource utilization among people living with COPD.
Ann Am Thorac Soc
September 2024
University Hospital Regensburg, Department of Internal Medicine II, Regensburg, Germany;
Rationale: Adherence to positive airway pressure (PAP) therapy is a common and challenging issue. Although some studies have looked at the impact of initial mask selection, there is a lack of data regarding the impact of a change in mask on adherence to PAP therapy.
Objective(s): This study investigated the impact of a mask change or renewal on mid-term PAP adherence.
Ann Am Thorac Soc
November 2024
University Grenoble Alpes and HP2 Laboratory, INSERM, Grenoble, France.
Three-year continuous positive airway pressure (CPAP) therapy termination rates are up to 50%, and therapy termination is associated with higher all-cause mortality and incident cardiovascular event risk. This study investigated the impact of CPAP therapy termination in the first year on long sick leave leading to permanent work disability in patients with obstructive sleep apnea based on data from the Nationwide Claims Data Lake for Sleep Apnoea (ALASKA). French national health insurance reimbursement system data were analyzed for all adults with OSA aged ≤62 years who started CPAP therapy in France in 2015 and 2016.
View Article and Find Full Text PDFJ Am Heart Assoc
May 2024
Charles Perkins Centre, Faculty of Medicine and Health University of Sydney Sydney Australia.
ERJ Open Res
January 2024
Department of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Background: Telemonitoring-guided interventions can improve short-term positive airway pressure (PAP) therapy adherence, but long-term effects are unknown. This study investigated long-term PAP therapy termination in patients with sleep apnoea managed with standard care, telemonitoring-guided proactive care or telemonitoring-guided proactive care + patient engagement tool.
Methods: German healthcare provider data were analysed retrospectively.
ERJ Open Res
January 2024
Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, National Heart and Lung Institute, Imperial College London, London, UK.
Background: A analysis of the MERGE trial was conducted, to investigate whether sex differences are evident at the mildest end of the disease spectrum, for symptoms associated with obstructive sleep apnoea (OSA) and the response to continuous positive airway pressure (CPAP) treatment.
Methods: MERGE participants with mild OSA (apnoea-hypopnoea index 5-15 events·h; American Academy of Sleep Medicine 2012 criteria) were randomised to either CPAP plus standard care (sleep hygiene counselling) or standard care alone for 3 months. Quality of life (QoL) was measured by questionnaires completed before and after the 3 months.
Ann Am Thorac Soc
April 2024
Sleep and Ventilation Center Blaubeuren, Ulm, Germany.
Adaptive servo-ventilation (ASV) effectively treats sleep-disordered breathing, including central sleep apnea (CSA) and coexisting obstructive sleep apnea (OSA). The prospective, multicenter European READ-ASV (Registry on the Treatment of Central and Complex Sleep-Disordered Breathing with Adaptive Servo-Ventilation) registry investigated the effects of first-time ASV therapy on disease-specific quality of life (QoL). The registry enrolled adults with CSA with or without OSA who had ASV therapy prescribed between September 2017 and March 2021.
View Article and Find Full Text PDFOpen Respir Arch
December 2023
Université Paris Cité, Paris, France.
Chest
May 2024
Sleep Disorders Center, Division of Pulmonary and Critical Care Medicine, Department of Medicine; and Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD.
Background: Positive airway pressure (PAP) therapy is first-line therapy for OSA, but consistent use is required for it to be effective. Previous studies have used Medicare fee-for-service claims data (eg, device, equipment charges) as a proxy for PAP adherence to assess its effects. However, this approach has not been validated in a US commercially insured population, where coverage rules are not standardized.
View Article and Find Full Text PDFJ Clin Sleep Med
May 2024
Departamento de Neurociências e Ciências do Comportamento, Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, Sao Paulo, Brazil.
Study Objectives: Obstructive sleep apnea (OSA) is highly prevalent, and positive airway pressure (PAP) therapy is the primary treatment. This study aimed to assess the diagnostic and PAP treatment resources for OSA within Brazil's Unified Health System and to identify potential inequalities and gaps.
Methods: A structured survey was sent to members of the Brazilian Sleep Association and the Brazilian Association of Sleep Medicine to identify sleep laboratories providing OSA diagnosis and/or treatment within Brazil's Unified Health System.
J Affect Disord
March 2024
Univ. Grenoble Alpes, Institut National de la Santé et de la Recherche Médicale (INSERM) U 1300, HP2 Laboratory (Hypoxia: Pathophysiology), Grenoble Alpes University, Grenoble, France.
Objective: Previous studies have shown that treatment of obstructive sleep apnea (OSA) with positive airway pressure (PAP) therapy in patients with depression may improve depression symptoms and response to antidepressant therapy. We investigated the association between PAP therapy adherence, self-harm events, healthcare resource utilization (HCRU), and costs over 2 years in a national sample of patients with pre-existing depression and newly diagnosed comorbid OSA.
Methods: Administrative claims data were linked to objective PAP therapy usage.
Eur Respir J
February 2024
University Grenoble Alpes, Inserm, CHU Grenoble Alpes, HP2, Grenoble, France.
Background: Continuation of continuous positive airway pressure (CPAP) therapy after initial prescription has been shown to reduce all-cause mortality therapy termination. However, there is a lack of data on the rates and impact of resuming CPAP in patients with obstructive sleep apnoea (OSA). This analysis determined the prevalence of CPAP resumption in the year after termination, characterised determinants of CPAP resumption, and examined the impact of CPAP resumption on all-cause mortality.
View Article and Find Full Text PDFJ Allergy Clin Immunol Pract
December 2023
Propeller Health, Madison, Wis.
JAMA Netw Open
December 2023
University of California, San Diego, La Jolla.
Importance: Chronic obstructive pulmonary disease (COPD) is a respiratory condition that is associated with significant health and economic burden worldwide. Previous studies assessed the global current-day prevalence of COPD, but to better facilitate resource planning and intervention development, long-term projections are needed.
Objective: To assess the global burden of COPD through 2050, considering COPD risk factors.
J Sleep Res
August 2024
University of California San Diego, La Jolla, California, USA.
Obstructive sleep apnea (OSA) is a highly prevalent yet underdiagnosed disease that creates a large economic burden on the United States healthcare system. In this retrospective study, we tested the hypothesis that adherence to positive airway pressure (PAP) therapy, the 'gold standard' treatment for OSA, is associated with reduced healthcare resource utilisation and costs. We linked de-identified payer-sourced medical claims and objective PAP usage data for patients newly diagnosed with OSA.
View Article and Find Full Text PDFJ Clin Sleep Med
April 2024
Sleep Medicine Program, University Hospitals Cleveland Medical Center, Cleveland, Ohio.
Study Objectives: The aims of this study were to characterize obstructive sleep apnea (OSA) care pathways among commercially insured individuals in the United States and to investigate between-groups differences in population, care delivery, and economic aspects.
Methods: We identified adults with OSA using a large, national administrative claims database (January 1, 2016-February 28, 2020). Inclusion criteria included a diagnostic sleep test on or within ≤ 12 months of OSA diagnosis (index date) and 12 months of continuous enrollment before and after the index date.
Lancet Reg Health Eur
November 2023
Polyclinique Saint-Laurent, Rennes, France.
JAMIA Open
December 2023
ResMed Science Center, San Diego, CA, United States.
Objective: Changes in short-acting beta-agonist (SABA) use are an important signal of asthma control and risk of asthma exacerbations. Inhaler sensors passively capture SABA use and may provide longitudinal data to identify at-riskpatients. We evaluate the performance of several ML models in predicting daily SABA use for participants with asthma and determine relevant features for predictive accuracy.
View Article and Find Full Text PDFBackground Obstructive sleep apnea (OSA) is common in heart failure with preserved ejection fraction (HFpEF). However, current evidence is equivocal regarding the potential benefits of treating OSA with positive airway pressure (PAP) therapy in HFpEF. This study assessed the association between adherence to PAP therapy and health care resource use in patients with OSA and HFpEF.
View Article and Find Full Text PDFFront Digit Health
June 2023
Verily Life Sciences, South San Francisco, CA, United States.
Purpose: This single-arm, decentralized pilot study assessed patient journey, positive airway pressure (PAP) usage and program satisfaction for users of an entirely virtual telemedicine program for obstructive sleep apnea (OSA) diagnosis and management. This analysis focuses specifically on the subset of participants in the program who were diagnosed with OSA and prescribed PAP therapy.
Methods: The Verily Clinical Studies Platform was used for virtual screening, consent, and enrolling eligible patients from North Carolina and Texas.
Cost Eff Resour Alloc
June 2023
Cleveland Clinic, Cleveland, OH, USA.
Background: Chronic obstructive pulmonary disease (COPD) is a progressive debilitating condition with frequent exacerbations that have a high burden for patients and society. Digital tools may help to reduce the economic burden for patients and payers by improving outcomes. The Propeller platform is a digital self-management tool that facilitates passive monitoring of inhaler medication utilization, potentially assisting the healthcare team to identify patients at risk of a COPD exacerbation who may require further intervention.
View Article and Find Full Text PDFAsthma Res Pract
May 2023
Wayne Children's Healthcare Access Program, Inc, Dba Kids' Health Connections, Detroit, USA.
Background: Real-world evidence for digitally-supported asthma programs among Medicaid-enrolled children remains limited. Using data from a collaborative quality improvement program, we evaluated the impact of a digital intervention on asthma inhaler use among children in southwest Detroit.
Methods: Children (6-13 years) enrolled with Kids Health Connection (KHC), a program involving home visits with an asthma educator, were invited to participate in a digital self-management asthma program (Propeller Health).
J Am Heart Assoc
May 2023
Department of Cardiovascular Medicine, Mayo Clinic Rochester MN.
Background Obstructive sleep apnea (OSA) is a common comorbidity in patients with heart failure, although current evidence is equivocal regarding the potential benefits of treating OSA with positive airway pressure (PAP) therapy in patients with heart failure. This study assessed the impact of adherence to PAP therapy on health care resource utilization in patients with OSA and heart failure with reduced ejection fraction. Methods and Results Administrative insurance claims data linked with objective PAP therapy use data from patients with OSA and heart failure with reduced ejection fraction were used to determine associations between PAP adherence and a composite outcome of hospitalizations and emergency room visits.
View Article and Find Full Text PDFAnn Am Thorac Soc
August 2023
ResMed Science Center, Sydney, New South Wales, Australia.